We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Urinary Microbiome Linked to Prostate Cancer Risk

By LabMedica International staff writers
Posted on 02 May 2022
Print article
Image: MinION sequencing device was used on three novel species for hybrid assembly (Photo courtesy of Oxford Nanopore Technologies)
Image: MinION sequencing device was used on three novel species for hybrid assembly (Photo courtesy of Oxford Nanopore Technologies)

Prostate cancer is the most common non-skin malignancy in men in developed countries, with over 250,000 deaths annually worldwide. The clinical course of prostate cancer is highly heterogeneous, and critical decisions are made about the likelihood of aggressive disease based on information obtained at presentation.

Determining urinary biomarkers to identify aggressive prostate cancer is an area of growing interest. Material secreted by the prostate gland appears in the urine, and reflux of urine into the prostate is well established, supporting the existence of a prostate-urine loop.

Urology Oncologists at the Norwich Medical School (Norwich, UK) used urine samples collected from 318 people in the UK who were being assessed for prostate cancer or for blood in their urine. They then examined the patients’ health outcomes for up to six years after the sample was taken. Urine sediments and extracellular vesicle fractions were prepared, with an additional step for the detection of bacteria by microscopy. Prostate secretions were collected via manual compression of the excised prostate less than 20 minutes after prostatectomy.

DNA was extracted from urine sediment with repeated bead-beating extraction to maximize bacterial DNA yield. Bacterial 16S DNA was amplified and sequenced (V1-V3/V3-V5 hypervariable regions). Quantitative polymerase chain reaction (qPCR) assays detected several bacterial genera and species. Urine extracellular vesicle total RNA was extracted from 40 urine samples and were sequenced.

Urine or prostate secretion samples were inoculated into pre-reduced PY broth or Brucella blood agar plates with 5% sheep blood and vitamin K1/hemin supplementation (Becton Dickinson GmbH, Heidelberg, Germany), and grown in an anaerobic cabinet. Pure colonies were picked and prepared for DNA extraction, and sequenced with Nextera XT library preparation on a MiSeq (Illumina, San Diego, CA, USA) using V3 reagents (2 × 300 bp). MinION nanopore sequencing (Oxford Nanopore Technologies, Oxford, UK) was used on three novel species for hybrid assembly (Unicycler).

The investigators demonstrated an association between the presence of bacteria in urine sediments and higher D’Amico risk prostate cancer. Characterization of the bacterial community led to the identification of four novel bacteria (Porphyromonas sp. nov., Varibaculum sp. nov., Peptoniphilus sp. nov., and Fenollaria sp. nov.) that were frequently found in patient urine, and a definition of a patient subgroup associated with metastasis development. The presence of five specific anaerobic genera, which includes three of the novel isolates, was associated with cancer risk group, in urine sediment, urine extracellular vesicles, and cancer tissue, with a meta-analysis hazard ratio for disease progression of 2.60.

Rachel Hurst, PhD, a Senior Research Associate and first author of the study, said, “We have identified a group of five bacterial genera linked with high-grade prostate cancer and more rapid progression to aggressive cancer.”

The authors concluded that their results established the importance of bacteria present in urine and the prostate as potential prognostic markers and, when considered together with data from other studies, provide a starting point for future investigations into the roles of bacteria in prostate cancer pathogenesis and evolution. The study was published on April 18, 2022 in the journal European Urology Oncology.

Related Links:
Norwich Medical School 
Becton Dickinson 
Illumina 
Oxford Nanopore Technologies 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Uric Acid and Blood Glucose Meter
URIT-10
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.